Clinical trial
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
Active, not recruiting · Phase 3 · 5 countries · Registry ID NCT06993792
Active, not recruitingPhase 3Interventional
What this study is about
The purpose of this Master Protocol is to support two studies to see how well and how safely orforglipron works compared to placebo in participants who have obesity or overweight with or without type 2 diabetes. Participants will be screened for about 4 weeks, after which they will enroll into either J2A-MC-GZP1, NCT06972459 (do not have type 2 diabetes) or J2A-MC-GZP2, NCT06972472 (have type 2 diabetes).
A promising-looking record is not the same as confirmed eligibility. The study team must review the full criteria and current recruitment status.
Basic eligibility
Age18 Years to Not listed
SexAll
Healthy volunteersNot accepted
ConditionObesity, Overweight, Type 2 Diabetes
Full registry criteria
There are no specific eligibility criteria for the Master Protocol. * See study GZP1 for eligibility criteria relevant to participants with obesity and overweight without type 2 diabetes * See study GZP2 for eligibility criteria relevant to participants with type 2 diabetes
Treatments and study arms
Orforglipron
Drug
Administered orally
Placebo
Drug
Administered orally
Primary outcomes
Number of Participants Allocated to Each StudyBaseline to Week 4
Study locations
80 locations were listed when this page was built. The first 40 are shown.
CARE - Centro de Alergia y Enfermedades Respiratorias🇦🇷 Buenos Aires, Argentina
CIPREC🇦🇷 Buenos Aires, Argentina
Centro Médico Viamonte🇦🇷 Buenos Aires, Argentina
Instituto Centenario🇦🇷 CABA, Argentina
Instituto Médico Catamarca IMEC🇦🇷 Rosario, Argentina
Centro de Diagnóstico y Rehabilitación (CEDIR)🇦🇷 Santa Fe, Argentina
Peking University Third Hospital🇨🇳 Beijing, China
Xuanwu Hospital Capital Medical University🇨🇳 Beijing, China
Sichuan Provincial People's Hospital🇨🇳 Chengdu, China
The Second Affiliated Hospital Chongqing Medical University🇨🇳 Chongqing, China
Zhujiang Hospital🇨🇳 Guangzhou, China
The Fourth Affiliated Hospital of Harbin Medical University🇨🇳 Harbin, China
The Second People's Hospital of Hefei🇨🇳 Hefei, China
Jinan Central Hospital🇨🇳 Jinan, China
The First Affiliated Hospital of Henan University of Science &Technology🇨🇳 Luoyang Shi, China
The Second Affiliated Hospital of Nanjing Medical University🇨🇳 Nanjing, China
Zhongda Hospital Southeast University🇨🇳 Nanjing, China
The Second Hospital of Tianjin Medical University🇨🇳 Tianjin, China
Donmed s.r.o.🇨🇿 Ostrava, Czechia
Milan Kvapil s.r.o., Diabetologicka ambulance🇨🇿 Prague, Czechia
Medical Plus🇨🇿 Uherské Hradiště, Czechia
MUDr. Alena Vachova🇨🇿 České Budějovice, Czechia
Nemocnice Cesky Krumlov🇨🇿 Český Krumlov, Czechia
InnoDiab Forschung Gmbh🇩🇪 Essen, Germany
Medizentrum Essen Borbeck🇩🇪 Essen, Germany
Diabetes Zentrum Wilhelmsburg🇩🇪 Hamburg, Germany
AmBeNet GmbH🇩🇪 Leipzig, Germany
Gemeinschaftspraxis Dr. Taeschner/Dr. Bonigut🇩🇪 Leipzig, Germany
Medicover Neuroendokrinologie🇩🇪 Munich, Germany
RED-Institut GmbH🇩🇪 Oldenburg, Germany
Hasegawa Medicine Clinic🇯🇵 Chitose, Japan
Fukuwa Clinic🇯🇵 Chūōku, Japan
The Institute of Medical Science, Asahi Life Foundation🇯🇵 Chūōku, Japan
Tokyo-Eki Center-building Clinic🇯🇵 Chūōku, Japan
Tokuyama Clinic🇯🇵 Mihama-ku,Chiba City, Japan
Medical Corporation Heishinkai ToCROM Clinic🇯🇵 Shinjuku-ku, Japan
Medical Corporation Heishinkai OCROM Clinic🇯🇵 Suita-shi, Japan
Olive Takamatsu Medical Clinic🇯🇵 Takamatsu, Japan
Shimokitazawa Tomo Clinic🇯🇵 Tokyo, Japan
Tsuchiura Medical & Health Care Center🇯🇵 Tsuchiura, Japan